HLA class II polymorphisms as prognostic biomarkers for right and left-sided colon cancer.

Amani AttiaAwatef LaghaAmel MezliniEzzedine GhazouaniBasma Yaacoubi-LoueslatiImene Namouchi

Published in: The International journal of biological markers (2024)

DRB1 and DQB1 polymorphisms could be used as future biomarkers for the early detection of subjects at a higher risk of developing RCC and LCC, metastasis in sigmoid CC, and tolerance to treatment in RCC.

Keyphrases

renal cell carcinoma
current status
combination therapy
replacement therapy